Apex Meds Get started
All peptides

TB-500 · Recovery & repair Modelled on
your body's own
repair signal.

TB-500 prescribed on its own for people focused on soft-tissue recovery. Evaluated by a licensed Apex Meds provider and filled by a licensed U.S. pharmacy.

$249per month · injectable
Apex Meds TB-500 vial
Form
Subcutaneous injection
Course
A loading phase, then maintenance
Prescribed by
Licensed Apex Meds provider
Derived from
Thymosin beta-4
What is TB-500?

TB-500, in plain terms

Thymosin beta-4 is a 43-amino-acid protein found in nearly every human cell and concentrated in platelets and wound fluid. TB-500 is a short synthetic fragment that copies the segment of that protein which binds actin.

The two are related but not identical. Most published research, and all of the human trial data, studied the full-length protein rather than the fragment.

What the research shows
What it has been studied for

The findings, and the kind of study behind each

Wound closure

In rats, thymosin beta-4 sped skin wound closure, up 42% at day four and 61% at day seven.

Animal and lab

Tendon strength

In a rat Achilles repair model, four weeks of TB-500 raised the load the tendon could bear.

Animal and lab

Safety of the parent protein

Forty healthy volunteers received thymosin beta-4 for up to 14 days with no serious adverse events.

Human study

The fragment in people

No human trial has tested TB-500 itself, or any thymosin product for athletic recovery.

Not yet studied
Who asks about it

People focused on soft-tissue recovery

Shoulders, tendons, soft tissue

People managing soft-tissue strain alongside their rehab.

Heavy training blocks

People who train hard and want a physician-guided recovery plan.

Coming back from injury

People returning from a setback who want oversight, not guesswork.

Staying in the game

People who want to keep doing what they love for longer.

These describe the people who ask about TB-500, not results. A licensed provider decides whether it is appropriate for you.

How it works

What it does in the body

Thymosin beta-4 binds actin, the building block of a cell's internal scaffolding. That lets cells change shape and move, which is how skin, blood-vessel and repair cells reach injured tissue.

In animal models the full protein also supported new blood vessel growth and lowered inflammatory signalling. How much of that the fragment shares is still being worked out.

Cell movement

Binds actin, the scaffolding that lets cells travel

Blood vessels

The full protein supported new vessel growth in animals

Inflammatory signalling

Lowered in animal models of the full protein

What to expect

On the protocol

01

How it's taken

Small injections just under the skin, usually more frequent at first and then less often. Your provider sets the dose and the schedule. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.

02

What people report

Patients commonly describe changes in soreness or mobility over the first several weeks. These are patient reports, not trial outcomes, and results vary.

03

Keep your care team

Peptides are not a substitute for diagnosis, physical therapy or orthopaedic care. Tell your provider about any injury you are treating.

Why Apex Meds

A higher standard in peptide therapy

  • Reviewed by a licensed provider
  • Filled by a licensed U.S. pharmacy
  • Arrives reconstituted, ready to use
  • Made for human use, never “research only”
  • Medical support while you are on it
Start my evaluation
Frequently asked questions

TB-500 questions, answered

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic fragment of it. Most published research studied the full-length protein.

Is it FDA-approved?

No. When prescribed it is a compounded medication, which has not been reviewed by the FDA for safety, effectiveness or quality.

Has it been tested in people?

The full protein has, mainly as eye drops, a skin gel and intravenous safety studies. The injectable fragment has no published human trials.

How is it taken?

Usually as subcutaneous injections that are more frequent at first and then less often. Your provider sets the schedule.

Who should not take it?

Anyone with current or past cancer, anyone pregnant or nursing, and competitive athletes subject to testing.

What side effects are reported?

Mostly injection-site reactions, headache and temporary tiredness. Long-term effects have not been studied.

I compete in a drug-tested sport. Can I use it?

No. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times under World Anti-Doping Agency rules.

What should I know before I start?

Your provider reviews your full history, so tell them about every medication and condition, including any history of cancer. Reported side effects: irritation at the injection site; headache; temporary tiredness or lightheadedness; nausea; long-term safety has not been studied. Who should not use it: active cancer or any history of cancer without oncologist clearance; pregnancy or breastfeeding; anyone under 18; athletes subject to drug testing.

Keep looking

Other peptides from Apex Meds

Physician-prescribed peptide therapy

Start with TB-500

Answer a few questions. A licensed Apex Meds provider decides whether it is right for you.

  • Expert guidance
  • Personalised care
  • Ongoing support

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.

Sources
  1. Malinda et al., J Invest Dermatol, 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
  2. Ruff et al., Ann N Y Acad Sci, 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
  3. Sosne et al., phase 2 trial, 2015. https://pubmed.ncbi.nlm.nih.gov/26056426/
  4. Bicer et al., Joint Diseases and Related Surgery, 2026. https://pubmed.ncbi.nlm.nih.gov/42542926/
  5. FDA evaluation of TB-500, 2026. https://www.fda.gov/media/193349/download